Evidence map›Paper›PMID 33357195›Full record

ReviewCurrent neuropharmacology2021

Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Sonia Mayo, Julián Benito-León, Carmen Peña-Bautista, Miguel Baquero, Consuelo Cháfer-Pericás

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. LC-MS/MS proteomics identifies plasma proteins related to cognition over 9-year follow-up.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Sonia MayoOxidative Pathology Research Group, Health Research Institute INCLIVA, Valencia, Spain.
Julián Benito-LeónDepartment of Neurology, University Hospital 12 de Octubre, Madrid, Spain.
Carmen Peña-BautistaNeonatal Research Unit, Health Research Institute La Fe, Valencia, Spain.
Miguel BaqueroNeurology Unit, University and Polytechnic Hospital La Fe, Valencia, Spain.
Consuelo Cháfer-PericásNeonatal Research Unit, Health Research Institute La Fe, Valencia, Spain.
Leitat Technological Center · ESHospital Universitari i Politècnic La Fe · ESINCLIVA Health Research Institute · ESResearch Institute Hospital 12 de Octubre · ES

Funding

Health Institute Carlos III (Spanish Ministry of Economy, Industry and Innovation)(FIS Grant) FIS PI19/00570Health Institute Carlos III (Spanish Ministry of Economy, Industry and Innovation) (“Miguel Servet Grant”) CP16/00082
6 · The paper itself

Abstract

backgroundAlzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly folded modified proteins. Protein expression mechanisms are involved since the early stages. Several studies evaluated epigenomics and proteomics profiles in these patients, with promising results. In general, they focused on early, specific, and minimally invasive biomarkers for the diagnosis and prognosis of AD and PD.

objectivesThis review aimed at summarizing results to find the most reliable evidence in the field.

resultsAmong epigenomics studies, there is a focus on microRNAs (miRNAs) as candidate diagnostic biomarkers for AD or PD from blood samples like miR-342-3p, miR-107, miR-106a-5p, miR-106b- 5p, miR-195, and miR-19b. In addition, DNA methylation has been tested in a few works, obtaining significant differences in some genes (NCAPH2/LMF2 COASY, SPINT1, BDNFTREM1, TREM2, NPAS2, PDE4D), which could be useful for evaluating the disease progression as well as potential risk factors. Regarding proteomics, most of the studies were untargeted and used plasma or serum samples. In general, they highlighted the importance of coagulation, inflammation pathways, and oxidative stress. Among targeted studies, some proteins (phosphorylated tau, C reactive protein (CRP), interleukins, necrosis factors, transferrin, glial fibrillary acidic protein (GFAP), and neurofilaments) showed different plasma levels in AD and PD patients in comparison with healthy participants. Finally, a few studies have identified specific-AD and PD epigenetic and proteomic biomarkers (ApoE and oxidized DJ-1) in comparison with other similar pathologies.

conclusionIn general, there is a common lack of clinical validation of these potential biomarkers because of which its use in clinical practice is still limited.

Indexed as

Alzheimer DiseaseMicroRNAsParkinson DiseaseBiomarkersEpigenomicsHumansMembrane GlycoproteinsProteomicsReceptors, ImmunologicTransferasesBiomarkersCOASY protein, humanMembrane GlycoproteinsMicroRNAsMIRN195 microRNA, humanReceptors, ImmunologicTransferasesTREM2 protein, humanAlzheimer's diseasebiomarkersdiagnosisearly.epigenomicsParkinson's diseaseproteomics

Identifiers

PMID33357195
PMCPMC8719284
OpenAlexW3117645897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.